Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism
نویسندگان
چکیده
منابع مشابه
Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial
Background: Low-Molecular-Weight Heparin (LMWH) is recommended as the first-line treatment in patients with active cancer and venous thromboembolism (VTE), but many patients prefer to take oral anticoagulants and non-injectable forms with more reasonable price. Venous thromboembolism is a very common comorbidity in patients with cancer. Therefore, the aim of this study was to evaluate the effic...
متن کاملRivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
BACKGROUND Patients with renal impairment receiving classical anticoagulation for venous thromboembolism (VTE) are at increased risk of bleeding and possibly pulmonary embolism. We examined the efficacy and safety of oral rivaroxaban in patients with VTE with and without renal impairment. METHODS Prespecified subgroup analysis of the EINSTEIN DVT and EINSTEIN PE studies comparing fixed-dose r...
متن کاملOral rivaroxaban for symptomatic venous thromboembolism.
BACKGROUND Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. METHODS We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) ...
متن کاملLevels of coagulation factors and venous thromboembolism.
BACKGROUND AND OBJECTIVES Altered levels of coagulation factors have been included among the abnormalities that may increase the risk of venous thromboembolism (VTE) in otherwise healthy subjects. INFORMATION SOURCES According to the studies that have been carried to test this hypothesis only elevated levels of factor VIII and fibrinogen emerged as independent risk factors for VTE. STATE OF...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Advances in Clinical and Experimental Medicine
سال: 2015
ISSN: 1899-5276
DOI: 10.17219/acem/42147